NCT04786600View on ClinicalTrials.gov

A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

March 19, 2024

Study Completion Date

March 19, 2024

Conditions
Metastatic Colorectal Cancer
Interventions
DEVICE

Signatera ctDNA assay

Subjects will be tested with the Signatera ctDNA assay every 2 weeks.

DRUG

pre-specified sequence of FDA-approved drugs and drug combinations

Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations

Trial Locations (1)

32608

University of Florida, Gainesville

Sponsors

Collaborators (1)

Natera, Inc.
All Listed Sponsors
collaborator

Natera, Inc.

INDUSTRY

lead

University of Florida

OTHER

NCT04786600 - A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial | Biotech Hunter | Biotech Hunter